Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05091372 · ClinicalTrials.gov registry record · Phase 2
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
A Phase 2 study of Myeloma Multiple, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT05091372 is a Phase 2 study of Myeloma Multiple that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 94 participants, above the 73-participant average among 7 other Myeloma Multiple trials with a reported enrollment target (29% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05091372, a Phase 2 study of Myeloma Multiple, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
Conditions Studied
Interventions
- DRUG Belantamab mafodotin
- DRUG Lenalidomide
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05091372
The ClinicalTrials.gov registry entry for NCT05091372 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 73-participant average among 7 other Myeloma Multiple trials with a reported enrollment target (29% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myeloma Multiple appearing as the primary indexed condition, and to 2 interventions - of which Belantamab mafodotin is the first listed.
NCT05091372 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05091372 about?
NCT05091372 is a clinical study titled "Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma". To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
What is the current status of trial NCT05091372?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2022-12-01. Estimated completion is 2027-12-31.
What conditions does trial NCT05091372 study?
This clinical trial studies the following conditions: Myeloma Multiple.
What interventions are being tested in trial NCT05091372?
The interventions under investigation include: Belantamab mafodotin (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT05091372?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05091372 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma Multiple
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Limited-duration Teclistamab
RECRUITING · Phase 2
-
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
ACTIVE NOT RECRUITING · Phase 2
-
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RECRUITING · Phase 1
-
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.